Gillian P. Bates - Publications

King's College London, London, UK 
Genetics, Huntington's disease

151 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Landles C, Milton RE, Ali N, Flomen R, Flower M, Schindler F, Gomez-Paredes C, Bondulich MK, Osborne GF, Goodwin D, Salsbury G, Benn CL, Sathasivam K, Smith EJ, Tabrizi SJ, ... ... Bates GP, et al. Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington'S Disease Model. Brain Communications. 2: fcaa066. PMID 32954323 DOI: 10.1093/braincomms/fcaa066  0.68
2017 Bryant DT, Landles C, Papadopoulou AS, Benjamin AC, Duckworth JK, Rosahl T, Benn CL, Bates GP. Disruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice. Scientific Reports. 7: 11900. PMID 28928414 DOI: 10.1038/s41598-017-11630-1  0.68
2016 Hjerpe R, Bett JS, Keuss MJ, Solovyova A, McWilliams TG, Johnson C, Sahu I, Varghese J, Wood N, Wightman M, Osborne G, Bates GP, Glickman MH, Trost M, Knebel A, et al. UBQLN2 Mediates Autophagy-Independent Protein Aggregate Clearance by the Proteasome. Cell. PMID 27477512 DOI: 10.1016/j.cell.2016.07.001  0.68
2016 Tulino R, Benjamin AC, Jolinon N, Smith DL, Chini EN, Carnemolla A, Bates GP. SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice. Plos One. 11: e0145425. PMID 26815359 DOI: 10.1371/journal.pone.0145425  0.68
2015 McCourt AC, O'Donovan KL, Ekblad E, Sand E, Craufurd D, Rosser A, Sanders D, Stoy N, Rickards H, Wierup N, Bates GP, Björkqvist M, Quarrell O. Characterization of Gastric Mucosa Biopsies Reveals Alterations in Huntington's Disease. Plos Currents. 7. PMID 26581667 DOI: 10.1371/currents.hd.858b4cc7f235df068387e9c20c436a79  0.68
2015 Carnemolla A, Lazell H, Moussaoui S, Bates GP. In Vivo Profiling Reveals a Competent Heat Shock Response in Adult Neurons: Implications for Neurodegenerative Disorders. Plos One. 10: e0131985. PMID 26134141 DOI: 10.1371/journal.pone.0131985  0.68
2015 Mielcarek M, Toczek M, Smeets CJ, Franklin SA, Bondulich MK, Jolinon N, Muller T, Ahmed M, Dick JR, Piotrowska I, Greensmith L, Smolenski RT, Bates GP. HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy. Plos Genetics. 11: e1005021. PMID 25748626 DOI: 10.1371/journal.pgen.1005021  0.68
2014 Neueder A, Bates GP. A common gene expression signature in Huntington's disease patient brain regions. Bmc Medical Genomics. 7: 60. PMID 25358814 DOI: 10.1186/s12920-014-0060-2  0.68
2014 Mielcarek M, Bondulich MK, Inuabasi L, Franklin SA, Muller T, Bates GP. The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model. Plos One. 9: e108961. PMID 25268775 DOI: 10.1371/journal.pone.0108961  0.68
2014 Corrochano S, Renna M, Osborne G, Carter S, Stewart M, May J, Bates GP, Brown SD, Rubinsztein DC, Acevedo-Arozena A. Reducing Igf-1r levels leads to paradoxical and sexually dimorphic effects in HD mice. Plos One. 9: e105595. PMID 25140802 DOI: 10.1371/journal.pone.0105595  0.68
2014 Mielcarek M, Inuabasi L, Bondulich MK, Muller T, Osborne GF, Franklin SA, Smith DL, Neueder A, Rosinski J, Rattray I, Protti A, Bates GP. Dysfunction of the CNS-heart axis in mouse models of Huntington's disease. Plos Genetics. 10: e1004550. PMID 25101683 DOI: 10.1371/journal.pgen.1004550  0.68
2014 Menalled LB, Kudwa AE, Oakeshott S, Farrar A, Paterson N, Filippov I, Miller S, Kwan M, Olsen M, Beltran J, Torello J, Fitzpatrick J, Mushlin R, Cox K, McConnell K, ... ... Bates GP, et al. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease. Plos One. 9: e99520. PMID 24955833 DOI: 10.1371/journal.pone.0099520  0.68
2014 Neueder A, Achilli F, Moussaoui S, Bates GP. Novel isoforms of heat shock transcription factor 1, HSF1γα and HSF1γβ, regulate chaperone protein gene transcription. The Journal of Biological Chemistry. 289: 19894-906. PMID 24855652 DOI: 10.1074/jbc.M114.570739  0.68
2014 Beaumont V, Park L, Rassoulpour A, Dijkman U, Heikkinen T, Lehtimaki K, Kontkanen O, Al Nackkash R, Bates GP, Gleyzes M, Steidl E, Ramboz S, Murphy C, Beconi MG, Dominguez C, et al. The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease. Plos Currents. 6. PMID 24558637 DOI: 10.1371/currents.hd.3304e87e460b4bb0dc519a29f4deccca  0.68
2014 Carnemolla A, Labbadia JP, Lazell H, Neueder A, Moussaoui S, Bates GP. Contesting the dogma of an age-related heat shock response impairment: implications for cardiac-specific age-related disorders. Human Molecular Genetics. 23: 3641-56. PMID 24556212 DOI: 10.1093/hmg/ddu073  0.68
2014 Träger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, McKinnon C, Sirinathsinghji E, Kahlon S, Pfister EL, Moser R, Hummerich H, Antoniou M, Bates GP, Luthi-Carter R, et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain : a Journal of Neurology. 137: 819-33. PMID 24459107 DOI: 10.1093/brain/awt355  0.68
2014 Schipper-Krom S, Juenemann K, Jansen AH, Wiemhoefer A, van den Nieuwendijk R, Smith DL, Hink MA, Bates GP, Overkleeft H, Ovaa H, Reits E. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies. Febs Letters. 588: 151-9. PMID 24291262 DOI: 10.1016/j.febslet.2013.11.023  0.68
2013 Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, Modo M. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease. Plos One. 8: e84726. PMID 24367693 DOI: 10.1371/journal.pone.0084726  0.68
2013 Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Osborne GF, Wadel K, Touller C, Butler R, Robertson J, Franklin SA, Smith DL, Park L, Marks PA, ... ... Bates GP, et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. Plos Biology. 11: e1001717. PMID 24302884 DOI: 10.1371/journal.pbio.1001717  0.68
2013 Mielcarek M, Seredenina T, Stokes MP, Osborne GF, Landles C, Inuabasi L, Franklin SA, Silva JC, Luthi-Carter R, Beaumont V, Bates GP. HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo. Plos One. 8: e80849. PMID 24278330 DOI: 10.1371/journal.pone.0080849  0.68
2013 Gipson TA, Neueder A, Wexler NS, Bates GP, Housman D. Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis. Rna Biology. 10: 1647-52. PMID 24256709 DOI: 10.4161/rna.26706  0.68
2013 Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A, Troncosco J, Ross CA, Bates GP, Krainc D, Sadri-Vakili G, et al. Targeting H3K4 trimethylation in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 110: E3027-36. PMID 23872847 DOI: 10.1073/pnas.1311323110  0.68
2013 O'Rourke JG, Gareau JR, Ochaba J, Song W, Raskó T, Reverter D, Lee J, Monteys AM, Pallos J, Mee L, Vashishtha M, Apostol BL, Nicholson TP, Illes K, Zhu YZ, ... ... Bates GP, et al. SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Reports. 4: 362-75. PMID 23871671 DOI: 10.1016/j.celrep.2013.06.034  0.68
2013 Rattray I, Smith E, Gale R, Matsumoto K, Bates GP, Modo M. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD. Plos One. 8: e60012. PMID 23593159 DOI: 10.1371/journal.pone.0060012  0.68
2013 Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, Detloff PJ, Housman DE, Bates GP. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 110: 2366-70. PMID 23341618 DOI: 10.1073/pnas.1221891110  0.68
2013 Horne EA, Coy J, Swinney K, Fung S, Cherry AE, Marrs WR, Naydenov AV, Lin YH, Sun X, Keene CD, Grouzmann E, Muchowski P, Bates GP, Mackie K, Stella N. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. The European Journal of Neuroscience. 37: 429-40. PMID 23167744 DOI: 10.1111/ejn.12045  0.68
2012 Weiss A, Träger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. The Journal of Clinical Investigation. 122: 3731-6. PMID 22996692 DOI: 10.1172/JCI64565  0.68
2012 Marcellin D, Abramowski D, Young D, Richter J, Weiss A, Marcel A, Maassen J, Kauffmann M, Bibel M, Shimshek DR, Faull RL, Bates GP, Kuhn RR, Van der Putten PH, Schmid P, et al. Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. Plos One. 7: e44457. PMID 22984513 DOI: 10.1371/journal.pone.0044457  0.68
2012 Beconi M, Aziz O, Matthews K, Moumné L, O'Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, et al. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. Plos One. 7: e44498. PMID 22973455 DOI: 10.1371/journal.pone.0044498  0.68
2012 Landles C, Weiss A, Franklin S, Howland D, Bates G. Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease. Plos Currents. 4: e4fd085bfc9973. PMID 22919566 DOI: 10.1371/4fd085bfc9973  0.68
2012 Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, Bates GP, Cheetham ME. Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain : a Journal of Neurology. 135: 1180-96. PMID 22396390 DOI: 10.1093/brain/aws022  0.68
2012 Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, Lo DC, Semmelroth M, Zivanovic A, Abramowski D, Smith D, Lotz GP, Bates GP, Weiss A. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chemistry & Biology. 19: 264-75. PMID 22365609 DOI: 10.1016/j.chembiol.2011.12.020  0.68
2012 Moumné L, Campbell K, Howland D, Ouyang Y, Bates GP. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. Plos One. 7: e31080. PMID 22347433 DOI: 10.1371/journal.pone.0031080  0.68
2011 Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. Plos One. 6: e27746. PMID 22140466 DOI: 10.1371/journal.pone.0027746  0.68
2011 Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, Seredenina T, Woodman B, Moussaoui S, Frentzel S, Luthi-Carter R, Paganetti P, Bates GP. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. The Journal of Clinical Investigation. 121: 3306-19. PMID 21785217 DOI: 10.1172/JCI57413  0.68
2011 Bobrowska A, Paganetti P, Matthias P, Bates GP. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. Plos One. 6: e20696. PMID 21677773 DOI: 10.1371/journal.pone.0020696  0.68
2011 van der Burg JM, Winqvist A, Aziz NA, Maat-Schieman ML, Roos RA, Bates GP, Brundin P, Björkqvist M, Wierup N. Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice. Neurobiology of Disease. 44: 1-8. PMID 21624468 DOI: 10.1016/j.nbd.2011.05.006  0.68
2011 Taylor DM, Balabadra U, Xiang Z, Woodman B, Meade S, Amore A, Maxwell MM, Reeves S, Bates GP, Luthi-Carter R, Lowden PA, Kazantsev AG. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. Acs Chemical Biology. 6: 540-6. PMID 21370928 DOI: 10.1021/cb100376q  0.68
2011 Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. The Journal of Clinical Investigation. 121: 476-83. PMID 21285520 DOI: 10.1172/JCI45364  0.68
2010 Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell MM, Reeves SA, Bates GP, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 107: 7927-32. PMID 20378838 DOI: 10.1073/pnas.1002924107  0.68
2010 Crittenden JR, Dunn DE, Merali FI, Woodman B, Yim M, Borkowska AE, Frosch MP, Bates GP, Housman DE, Lo DC, Graybiel AM. CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease. Human Molecular Genetics. 19: 1756-65. PMID 20147317 DOI: 10.1093/hmg/ddq055  0.68
2010 Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. The Journal of Biological Chemistry. 285: 8808-23. PMID 20086007 DOI: 10.1074/jbc.M109.075028  0.68
2010 Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, Finkbeiner S, Paganetti P, Muchowski PJ, Wilson S, Bates GP. Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Human Molecular Genetics. 19: 65-78. PMID 19825844 DOI: 10.1093/hmg/ddp467  0.68
2009 Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. Plos One. 4: e8025. PMID 19956633 DOI: 10.1371/journal.pone.0008025  0.68
2009 Bett JS, Benn CL, Ryu KY, Kopito RR, Bates GP. The polyubiquitin Ubc gene modulates histone H2A monoubiquitylation in the R6/2 mouse model of Huntington's disease. Journal of Cellular and Molecular Medicine. 13: 2645-57. PMID 19602042 DOI: 10.1111/j.1582-4934.2008.00543.x  0.68
2009 Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, Mielcarek M, Woodman B, Bates GP. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. Plos One. 4: e5747. PMID 19484127 DOI: 10.1371/journal.pone.0005747  0.68
2009 Bett JS, Cook C, Petrucelli L, Bates GP. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. Plos One. 4: e5128. PMID 19352500 DOI: 10.1371/journal.pone.0005128  0.68
2009 Zabel C, Mao L, Woodman B, Rohe M, Wacker MA, Kläre Y, Koppelstätter A, Nebrich G, Klein O, Grams S, Strand A, Luthi-Carter R, Hartl D, Klose J, Bates GP. A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. Molecular & Cellular Proteomics : McP. 8: 720-34. PMID 19043139 DOI: 10.1074/mcp.M800277-MCP200  0.68
2009 Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes. 58: 318-28. PMID 18984744 DOI: 10.2337/db08-0799  0.68
2008 Benn CL, Fox H, Bates GP. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. Molecular Neurodegeneration. 3: 17. PMID 18954449 DOI: 10.1186/1750-1326-3-17  0.68
2008 Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, ... ... Bates GP, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of Experimental Medicine. 205: 1869-77. PMID 18625748 DOI: 10.1084/jem.20080178  0.68
2008 Gonitel R, Moffitt H, Sathasivam K, Woodman B, Detloff PJ, Faull RL, Bates GP. DNA instability in postmitotic neurons. Proceedings of the National Academy of Sciences of the United States of America. 105: 3467-72. PMID 18299573 DOI: 10.1073/pnas.0800048105  0.68
2008 Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Régulier E, Bates GP, Paganetti P. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. Journal of Neurochemistry. 104: 846-58. PMID 17986219 DOI: 10.1111/j.1471-4159.2007.05032.x  0.68
2008 van der Burg JM, Bacos K, Wood NI, Lindqvist A, Wierup N, Woodman B, Wamsteeker JI, Smith R, Deierborg T, Kuhar MJ, Bates GP, Mulder H, Erlanson-Albertsson C, Morton AJ, Brundin P, et al. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease. 29: 41-51. PMID 17920283 DOI: 10.1016/j.nbd.2007.07.029  0.68
2007 Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR. Global changes to the ubiquitin system in Huntington's disease. Nature. 448: 704-8. PMID 17687326 DOI: 10.1038/nature06022  0.68
2007 Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. Journal of Proteome Research. 6: 2833-40. PMID 17552550 DOI: 10.1021/pr0700753  0.68
2007 Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, ... ... Bates GP, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/hmg/ddm133  0.68
2007 Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, Wells DJ, Latchman DS, de Belleroche J, Tabrizi SJ, Morimoto RI, Bates GP. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. Human Molecular Genetics. 16: 1078-90. PMID 17360721 DOI: 10.1093/hmg/ddm057  0.68
2007 Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, Moffitt H, Sathasivam K, Bates GP. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Research Bulletin. 72: 83-97. PMID 17352931 DOI: 10.1016/j.brainresbull.2006.11.004  0.68
2006 Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nature Reviews. Neuroscience. 7: 784-96. PMID 16988654 DOI: 10.1038/nrn1989  0.68
2006 Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease. 23: 190-7. PMID 16697652 DOI: 10.1016/j.nbd.2006.02.011  0.68
2006 Björkqvist M, Petersén A, Bacos K, Isaacs J, Norlén P, Gil J, Popovic N, Sundler F, Bates GP, Tabrizi SJ, Brundin P, Mulder H. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Human Molecular Genetics. 15: 1713-21. PMID 16613897 DOI: 10.1093/hmg/ddl094  0.68
2006 Bates GP. BIOMEDICINE: One Misfolded Protein Allows Others to Sneak By. Science (New York, N.Y.). 311: 1385-6. PMID 16527959 DOI: 10.1126/science.1125246  0.68
2006 Tsang TM, Woodman B, McLoughlin GA, Griffin JL, Tabrizi SJ, Bates GP, Holmes E. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. Journal of Proteome Research. 5: 483-92. PMID 16512662 DOI: 10.1021/pr050244o  0.68
2006 Bates GP, Gonitel R. Mouse models of triplet repeat diseases. Molecular Biotechnology. 32: 147-58. PMID 16444016 DOI: 10.1385/MB:32:2:147  0.68
2006 Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Human Molecular Genetics. 15: 33-44. PMID 16311253 DOI: 10.1093/hmg/ddi423  0.68
2006 Hockly E, Tse J, Barker AL, Moolman DL, Beunard JL, Revington AP, Holt K, Sunshine S, Moffitt H, Sathasivam K, Woodman B, Wanker EE, Lowden PA, Bates GP. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiology of Disease. 21: 228-36. PMID 16111888 DOI: 10.1016/j.nbd.2005.07.007  0.68
2006 Bett JS, Bates GP, Hockly E. Molecular pathogenesis and therapeutic targets in Huntington's disease Genetic Instabilities and Neurological Diseases, Second Edition. 223-249. DOI: 10.1016/B978-012369462-1/50015-6  0.68
2005 Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Current Opinion in Neurology. 18: 698-705. PMID 16280682 DOI: 10.1097/01.wco.0000186842.51129.cb  0.68
2005 Papalexi E, Persson A, Björkqvist M, Petersén A, Woodman B, Bates GP, Sundler F, Mulder H, Brundin P, Popovic N. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. The European Journal of Neuroscience. 22: 1541-6. PMID 16190907 DOI: 10.1111/j.1460-9568.2005.04324.x  0.68
2005 Benn CL, Landles C, Li H, Strand AD, Woodman B, Sathasivam K, Li SH, Ghazi-Noori S, Hockly E, Faruque SM, Cha JH, Sharpe PT, Olson JM, Li XJ, Bates GP. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Human Molecular Genetics. 14: 3065-78. PMID 16183657 DOI: 10.1093/hmg/ddi340  0.68
2005 Bates GP. History of genetic disease: the molecular genetics of Huntington disease - a history. Nature Reviews. Genetics. 6: 766-73. PMID 16136077 DOI: 10.1038/nrg1686  0.68
2005 Smith R, Petersén A, Bates GP, Brundin P, Li JY. Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction. Neurobiology of Disease. 20: 673-84. PMID 15967669 DOI: 10.1016/j.nbd.2005.05.008  0.68
2005 Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, Messer A. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiology of Disease. 19: 47-56. PMID 15837560 DOI: 10.1016/j.nbd.2004.11.003  0.68
2005 Cornett J, Cao F, Wang CE, Ross CA, Bates GP, Li SH, Li XJ. Polyglutamine expansion of huntingtin impairs its nuclear export. Nature Genetics. 37: 198-204. PMID 15654337 DOI: 10.1038/ng1503  0.68
2005 Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America. 102: 892-7. PMID 15642944 DOI: 10.1073/pnas.0408936102  0.68
2004 Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. Embo Reports. 5: 958-63. PMID 15459747 DOI: 10.1038/sj.embor.7400250  0.68
2004 Smith DL, Bates GP. Monitoring aggregate formation in organotypic slice cultures from transgenic mice. Methods in Molecular Biology (Clifton, N.J.). 277: 161-71. PMID 15201455 DOI: 10.1385/1-59259-804-8:161  0.68
2004 Bates GP, Hay DG. Mouse models of triplet repeat diseases. Methods in Molecular Biology (Clifton, N.J.). 277: 3-15. PMID 15201445 DOI: 10.1385/1-59259-804-8:003  0.68
2004 Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith DL, Woodman B, Bates GP. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Human Molecular Genetics. 13: 1389-405. PMID 15115766 DOI: 10.1093/hmg/ddh144  0.68
2003 Hersch S, Fink K, Vonsattel JP, Friedlander RM. Minocycline is protective in a mouse model of Huntington's disease. Annals of Neurology. 54: 841; author reply 84. PMID 14681897 DOI: 10.1002/ana.21891  0.68
2003 Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, Young AB, Standaert DG, Thompson LM, Cha JH. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiology of Disease. 14: 624-36. PMID 14678777 DOI: 10.1016/j.nbd.2003.08.024  0.68
2003 Orth M, Cooper JM, Bates GP, Schapira AH. Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. Journal of Neurochemistry. 87: 1-6. PMID 12969246 DOI: 10.1046/j.1471-4159.2003.02009.x  0.68
2003 Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA, Bates GP, Hockly E. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Annals of Neurology. 54: 186-96. PMID 12891671 DOI: 10.1002/ana.10614  0.68
2003 Bates GP, Hockly E. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Current Opinion in Neurology. 16: 465-70. PMID 12869804 DOI: 10.1097/  0.68
2003 Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, ... Bates GP, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 100: 2041-6. PMID 12576549 DOI: 10.1073/pnas.0437870100  0.68
2002 Liévens JC, Woodman B, Mahal A, Bates GP. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Molecular and Cellular Neurosciences. 20: 638-48. PMID 12213445 DOI: 10.1006/mcne.2002.1152  0.68
2002 Zabel C, Chamrad DC, Priller J, Woodman B, Meyer HE, Bates GP, Klose J. Alterations in the mouse and human proteome caused by Huntington's disease. Molecular & Cellular Proteomics : McP. 1: 366-75. PMID 12118078  0.68
2002 Peters PJ, Ning K, Palacios F, Boshans RL, Kazantsev A, Thompson LM, Woodman B, Bates GP, D'Souza-Schorey C. Arfaptin 2 regulates the aggregation of mutant huntingtin protein. Nature Cell Biology. 4: 240-5. PMID 11854752 DOI: 10.1038/ncb761  0.68
2002 Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Annals of Neurology. 51: 235-42. PMID 11835380 DOI: 10.1002/ana.10094  0.68
2001 Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiology of Disease. 8: 1017-26. PMID 11741397 DOI: 10.1006/nbdi.2001.0438  0.68
2001 Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, Bates GP. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Human Molecular Genetics. 10: 2425-35. PMID 11689489  0.68
2001 Bates GP. Huntington's disease. Exploiting expression. Nature. 413: 691, 693-4. PMID 11607014 DOI: 10.1038/35099656  0.68
2001 Liévens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates GP. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiology of Disease. 8: 807-21. PMID 11592850 DOI: 10.1006/nbdi.2001.0430  0.68
2001 Waelter S, Scherzinger E, Hasenbank R, Nordhoff E, Lurz R, Goehler H, Gauss C, Sathasivam K, Bates GP, Lehrach H, Wanker EE. The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis. Human Molecular Genetics. 10: 1807-17. PMID 11532990  0.68
2001 Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. Journal of Neurochemistry. 78: 694-703. PMID 11520890 DOI: 10.1046/j.1471-4159.2001.00482.x  0.68
2001 Kusakabe M, Mangiarini L, Laywell ED, Bates GP, Yoshiki A, Hiraiwa N, Inoue J, Steindler DA. Loss of cortical and thalamic neuronal tenascin-C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene. The Journal of Comparative Neurology. 430: 485-500. PMID 11169482 DOI: 10.1002/1096-9861(20010219)430:4<485::AID-CNE1045>3.0.CO;2-6  0.68
2000 McGowan DP, van Roon-Mom W, Holloway H, Bates GP, Mangiarini L, Cooper GJ, Faull RL, Snell RG. Amyloid-like inclusions in Huntington's disease. Neuroscience. 100: 677-80. PMID 11036200 DOI: 10.1016/S0306-4522(00)00391-2  0.68
2000 Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 97: 8093-7. PMID 10869421 DOI: 10.1073/pnas.110078997  0.68
2000 Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 5115-23. PMID 10864968  0.68
2000 Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proceedings of the National Academy of Sciences of the United States of America. 97: 6763-8. PMID 10823891 DOI: 10.1073/pnas.100110097  0.68
1999 Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 10428-37. PMID 10575040  0.68
1999 Davies SW, Sathasivam K, Hobbs C, Doherty P, Mangiarini L, Scherzinger E, Wanker EE, Bates GP. Detection of polyglutamine aggregation in mouse models. Methods in Enzymology. 309: 687-701. PMID 10507055 DOI: 10.1016/S0076-6879(99)09045-X  0.68
1999 Cha JH, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, Penney JB, Davies SW, Bates GP, Young AB. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 981-9. PMID 10434296  0.68
1999 Davies SW, Turmaine M, Cozens BA, Raza AS, Mahal A, Mangiarini L, Bates GP. From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 981-9. PMID 10434295  0.68
1999 Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies SW, Bates GP. Transgenic models of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 963-9. PMID 10434294 DOI: 10.1098/rstb.1999.0447  0.68
1999 Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Human Molecular Genetics. 8: 1227-36. PMID 10369868 DOI: 10.1093/hmg/8.7.1227  0.68
1999 Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proceedings of the National Academy of Sciences of the United States of America. 96: 4604-9. PMID 10200309 DOI: 10.1073/pnas.96.8.4604  0.68
1999 Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker EE, Doherty P, Davies SW, Bates GP. Formation of polyglutamine inclusions in non-CNS tissue. Human Molecular Genetics. 8: 813-22. PMID 10196370  0.68
1999 Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 3248-57. PMID 10191337  0.68
1999 Reynolds GP, Dalton CF, Tillery CL, Mangiarini L, Davies SW, Bates GP. Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. Journal of Neurochemistry. 72: 1773-6. PMID 10098889 DOI: 10.1046/j.1471-4159.1999.721773.x  0.68
1999 Mangiarini L, Sathasivam K, Bates GP. Molecular pathology of Huntington's disease: Animal models and nuclear mechanisms Neuroscientist. 5: 383-391.  0.68
1998 Sittler A, Wälter S, Wedemeyer N, Hasenbank R, Scherzinger E, Eickhoff H, Bates GP, Lehrach H, Wanker EE. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Molecular Cell. 2: 427-36. PMID 9809064  0.68
1998 Bates GP, Mangiarini L, Davies SW. Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathology (Zurich, Switzerland). 8: 699-714. PMID 9804379  0.68
1998 Bates GP, Mangiarini L, Wanker EE, Davies SW. Polyglutamine expansion and Huntington's disease. Biochemical Society Transactions. 26: 471-5. PMID 9765898  0.68
1998 File SE, Mahal A, Mangiarini L, Bates GP. Striking changes in anxiety in Huntington's disease transgenic mice. Brain Research. 805: 234-40. PMID 9733972 DOI: 10.1016/S0006-8993(98)00736-7  0.68
1998 Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiology of Disease. 4: 387-97. PMID 9666478 DOI: 10.1006/nbdi.1998.0168  0.68
1998 Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proceedings of the National Academy of Sciences of the United States of America. 95: 6480-5. PMID 9600992 DOI: 10.1073/pnas.95.11.6480  0.68
1998 Bertaux F, Sharp AH, Ross CA, Lehrach H, Bates GP, Wanker E. HAP1-huntingtin interactions do not contribute to the molecular pathology in Huntington's disease transgenic mice. Febs Letters. 426: 229-32. PMID 9599014 DOI: 10.1016/S0014-5793(98)00352-4  0.68
1998 Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, Callen DF, Gribouval O, Broyer M, Bates GP, van't Hoff W, Antignac C. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nature Genetics. 18: 319-24. PMID 9537412 DOI: 10.1038/ng0498-319  0.68
1998 Davies SW, Beardsall K, Turmaine M, DiFiglia M, Aronin N, Bates GP. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet (London, England). 351: 131-3. PMID 9439509 DOI: 10.1016/S0140-6736(97)08360-8  0.68
1997 Pribill I, Barnes GT, Chen J, Church D, Buckler A, Baxendale S, Bates GP, Lehrach H, Gusella MJ, Duyao MP, Ambrose CM, Gusella JF, MacDonald ME. Exon trapping and sequence-based methods of gene finding in transcript mapping of human 4p16.3. Somatic Cell and Molecular Genetics. 23: 413-27. PMID 9661704  0.68
1997 Bates GP, Davies SW. Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions. Molecular Medicine Today. 3: 508-15. PMID 9430787 DOI: 10.1016/S1357-4310(97)01142-8  0.68
1997 Sathasivam K, Baxendale S, Mangiarini L, Bertaux F, Hetherington C, Kanazawa I, Lehrach H, Bates GP. Aberrant processing of the Fugu HD (FrHD) mRNA in mouse cells and in transgenic mice. Human Molecular Genetics. 6: 2141-9. PMID 9328479 DOI: 10.1093/hmg/6.12.2141  0.68
1997 DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (New York, N.Y.). 277: 1990-3. PMID 9302293 DOI: 10.1126/science.277.5334.1990  0.68
1997 Bates GP, Mangiarini L, Mahal A, Davies SW. Transgenic models of Huntington's disease. Human Molecular Genetics. 6: 1633-7. PMID 9300654 DOI: 10.1093/hmg/6.10.1633  0.68
1997 Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 90: 549-58. PMID 9267034 DOI: 10.1016/S0092-8674(00)80514-0  0.68
1997 Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90: 537-48. PMID 9267033 DOI: 10.1016/S0092-8674(00)80513-9  0.68
1997 Flint J, Bates GP, Clark K, Dorman A, Willingham D, Roe BA, Micklem G, Higgs DR, Louis EJ. Sequence comparison of human and yeast telomeres identifies structurally distinct subtelomeric domains. Human Molecular Genetics. 6: 1305-13. PMID 9259277 DOI: 10.1093/hmg/6.8.1305  0.68
1997 Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nature Genetics. 15: 197-200. PMID 9020849 DOI: 10.1038/ng0297-197  0.68
1996 Hadano S, Ishida Y, Tomiyasu H, Yamamoto K, Bates GP, Ikeda JE. Transcript map of the human chromosome 4p16.3 consisting of 627 cDNA clones derived from 1 Mb of the Huntington's disease locus. Dna Research : An International Journal For Rapid Publication of Reports On Genes and Genomes. 3: 239-55. PMID 8946164  0.68
1996 Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87: 493-506. PMID 8898202 DOI: 10.1016/S0092-8674(00)81369-0  0.68
1994 Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somatic Cell and Molecular Genetics. 20: 27-38. PMID 8197474 DOI: 10.1007/BF02257483  0.68
1994 Hummerich H, Baxendale S, Mott R, Kirby SF, MacDonald ME, Gusella J, Lehrach H, Bates GP. Distribution of trinucleotide repeat sequences across a 2 Mbp region containing the Huntington's disease gene. Human Molecular Genetics. 3: 73-8. PMID 8162055  0.68
1993 Snell RG, Doucette-Stamm LA, Gillespie KM, Taylor SA, Riba L, Bates GP, Altherr MR, MacDonald ME, Gusella JF, Wasmuth JJ. The isolation of cDNAs within the Huntington disease region by hybridisation of yeast artificial chromosomes to a cDNA library. Human Molecular Genetics. 2: 305-9. PMID 8499921  0.68
1993 MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B, Anderson MA, Wexler NS, Gusella JF, ... Bates GP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell. 72: 971-983. PMID 8458085 DOI: 10.1016/0092-8674(93)90585-E  0.68
1993 Baxendale S, MacDonald ME, Mott R, Francis F, Lin C, Kirby SF, James M, Zehetner G, Hummerich H, Valdes J. A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene. Nature Genetics. 4: 181-6. PMID 8348156 DOI: 10.1038/ng0693-181  0.68
1993 Tommerup N, Aagaard L, Lund CL, Boel E, Baxendale S, Bates GP, Lehrach H, Vissing H. A zinc-finger gene ZNF141 mapping at 4p16.3/D4S90 is a candidate gene for the Wolf-Hirschhorn (4p-) syndrome. Human Molecular Genetics. 2: 1571-5. PMID 8268908  0.68
1993 Hadano S, Ishida Y, Bates GP, Nagayama T, Kanazawa I, Lehrach H, Ikeda J. Generation of high-density DNA markers from yeast artificial chromosome DNA by single unique primer-polymerase chain reaction. Genetic Analysis, Techniques and Applications. 10: 105-8. PMID 8204302 DOI: 10.1016/1050-3862(93)90032-E  0.68
1992 Youngman S, Bates GP, Williams S, McClatchey AI, Baxendale S, Sedlacek Z, Altherr M, Wasmuth JJ, MacDonald ME, Gusella JF. The telomeric 60 kb of chromosome arm 4p is homologous to telomeric regions on 13p, 15p, 21p, and 22p. Genomics. 14: 350-6. PMID 1427851 DOI: 10.1016/S0888-7543(05)80225-3  0.68
1992 Taylor SA, Snell RG, Buckler A, Ambrose C, Duyao M, Church D, Lin CS, Altherr M, Bates GP, Groot N. Cloning of the alpha-adducin gene from the Huntington's disease candidate region of chromosome 4 by exon amplification. Nature Genetics. 2: 223-7. PMID 1345173 DOI: 10.1038/ng1192-223  0.68
1992 Bates GP, Valdes J, Hummerich H, Baxendale S, Le Paslier DL, Monaco AP, Tagle D, MacDonald ME, Altherr M, Ross M. Characterization of a yeast artificial chromosome contig spanning the Huntington's disease gene candidate region. Nature Genetics. 1: 180-7. PMID 1303232 DOI: 10.1038/ng0692-180  0.68
1991 Bates GP, MacDonald ME, Baxendale S, Youngman S, Lin C, Whaley WL, Wasmuth JJ, Gusella JF, Lehrach H. Defined physical limits of the Huntington disease gene candidate region. American Journal of Human Genetics. 49: 7-16. PMID 1829581  0.68
1991 Baxendale S, Bates GP, MacDonald ME, Gusella JF, Lehrach H. The direct screening of cosmid libraries with YAC clones. Nucleic Acids Research. 19: 6651. PMID 1754409 DOI: 10.1093/nar/19.23.6651  0.68
1991 Lin CS, Altherr M, Bates G, Whaley WL, Read AP, Harris R, Lehrach H, Wasmuth JJ, Gusella JF, MacDonald ME. New DNA markers in the Huntington's disease gene candidate region. Somatic Cell and Molecular Genetics. 17: 481-8. PMID 1684879 DOI: 10.1007/BF01233172  0.68
1991 Whaley WL, Bates GP, Novelletto A, Sedlacek Z, Cheng S, Romano D, Ormondroyd E, Allitto B, Lin C, Youngman S. Mapping of cosmid clones in Huntington's disease region of chromosome 4. Somatic Cell and Molecular Genetics. 17: 83-91. PMID 1671801 DOI: 10.1007/BF01233207  0.68
1990 Bates GP, MacDonald ME, Baxendale S, Sedlacek Z, Youngman S, Romano D, Whaley WL, Allitto BA, Poustka A, Gusella JF. A yeast artificial chromosome telomere clone spanning a possible location of the Huntington disease gene. American Journal of Human Genetics. 46: 762-75. PMID 2138410  0.68
1990 Bu?an M, Zimmer M, Whaley WL, Poustka A, Youngman S, Allitto BA, Ormondroyd E, Smith B, Pohl TM, MacDonald M, Bates GP, Richards J, Volinia S, Gilliam TC, Sedlacek Z, et al. Physical maps of 4p16.3, the area expected to contain the Huntington disease mutation Genomics. 6: 1-15. PMID 2137426 DOI: 10.1016/0888-7543(90)90442-W  0.68
1987 Estivill X, Farrall M, Scambler PJ, Bell GM, Hawley KM, Lench NJ, Bates GP, Kruyer HC, Frederick PA, Stanier P. A candidate for the cystic fibrosis locus isolated by selection for methylation-free islands. Nature. 326: 840-5. PMID 2883581 DOI: 10.1038/326840a0  0.68
1987 Bates GP, Williamson R. RFLP for pHM20 (D2S12), an anonymous DNA sequence localised to 2p23-2pter. Nucleic Acids Research. 15: 864. PMID 2881265 DOI: 10.1093/nar/15.2.864  0.68
1986 Bates GP, Wainwright BJ, Williamson R, Brown SD. Microdissection of and microcloning from the short arm of human chromosome 2. Molecular and Cellular Biology. 6: 3826-30. PMID 3796596  0.68
Show low-probability matches.